MAINZ BIOMED NV (MYNZ) Stock Price & Overview
NASDAQ:MYNZ • NL0015000LC2
The current stock price of MYNZ is 0.8661 USD. Today MYNZ is up by 3.54%. In the past month the price decreased by -25.97%. In the past year, price decreased by -85.09%.
MYNZ Key Statistics
- Market Cap
- 7.847M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -22.36
- Dividend Yield
- N/A
MYNZ Stock Performance
MYNZ Stock Chart
MYNZ Technical Analysis
ChartMill assigns a technical rating of 0 / 10 to MYNZ. When comparing the yearly performance of all stocks, MYNZ is a bad performer in the overall market: 95.92% of all stocks are doing better.
MYNZ Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to MYNZ. Both the profitability and financial health of MYNZ have multiple concerns.
MYNZ Earnings
MYNZ Forecast & Estimates
7 analysts have analysed MYNZ and the average price target is 14.28 USD. This implies a price increase of 1548.77% is expected in the next year compared to the current price of 0.8661.
For the next year, analysts expect an EPS growth of 83.39% and a revenue growth -17.68% for MYNZ
MYNZ Groups
Sector & Classification
MYNZ Financial Highlights
Over the last trailing twelve months MYNZ reported a non-GAAP Earnings per Share(EPS) of -22.36. The EPS increased by 65.47% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -220.85% | ||
| ROE | -858.34% | ||
| Debt/Equity | 0.44 |
MYNZ Ownership
MYNZ Latest News, Press Relases and Analysis
MYNZ Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 16.15 | 413.319B | ||
| AMGN | AMGEN INC | 16.79 | 203.007B | ||
| GILD | GILEAD SCIENCES INC | 16.57 | 183.41B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.4 | 120.332B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.8 | 81.051B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 48.2 | 42.097B | ||
| INSM | INSMED INC | N/A | 31.351B | ||
| NTRA | NATERA INC | N/A | 29.344B | ||
| BIIB | BIOGEN INC | 12.28 | 27.007B | ||
| UTHR | UNITED THERAPEUTICS CORP | 16.39 | 21.856B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 19.914B | ||
| EXAS | EXACT SCIENCES CORP | 309 | 19.724B | ||
| MRNA | MODERNA INC | N/A | 19.468B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About MYNZ
Company Profile
Mainz Biomed NV is a molecular genetics cancer diagnostic company. The company is headquartered in Mainz, Hessen and currently employs 19 full-time employees. The company went IPO on 2021-11-04. The firm operates under one segment, namely genetic diagnostic testing services. Its portfolio consists of various products and product candidates, such as ColoAlert, a colorectal cancer (CRC) screening stool-based DNA (deoxyribonucleic acid) test; PancAlert, a stool-based screening test for the detection of pancreatic cancer; GenoStrip, a platform technology to detect pathogens in environments on a molecular genetic basis. The firm competes with Exact Sciences, Epigenomics AG, Novigenix SA, GRAIL, Inc. and Agena Biosciences Inc.
Company Info
MAINZ BIOMED NV
Sirius Gutenberg Park, Robert-Koch-Strasse 50
MAINZ HESSEN DE
Employees: 23
Phone: 496131265140
MAINZ BIOMED NV / MYNZ FAQ
What does MYNZ do?
Mainz Biomed NV is a molecular genetics cancer diagnostic company. The company is headquartered in Mainz, Hessen and currently employs 19 full-time employees. The company went IPO on 2021-11-04. The firm operates under one segment, namely genetic diagnostic testing services. Its portfolio consists of various products and product candidates, such as ColoAlert, a colorectal cancer (CRC) screening stool-based DNA (deoxyribonucleic acid) test; PancAlert, a stool-based screening test for the detection of pancreatic cancer; GenoStrip, a platform technology to detect pathogens in environments on a molecular genetic basis. The firm competes with Exact Sciences, Epigenomics AG, Novigenix SA, GRAIL, Inc. and Agena Biosciences Inc.
What is the stock price of MAINZ BIOMED NV today?
The current stock price of MYNZ is 0.8661 USD. The price increased by 3.54% in the last trading session.
What is the dividend status of MAINZ BIOMED NV?
MYNZ does not pay a dividend.
How is the ChartMill rating for MAINZ BIOMED NV?
MYNZ has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What is the expected growth for MYNZ stock?
The Revenue of MAINZ BIOMED NV (MYNZ) is expected to decline by -17.68% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
What is the Short Interest ratio of MAINZ BIOMED NV (MYNZ) stock?
The outstanding short interest for MAINZ BIOMED NV (MYNZ) is 2.97% of its float.